- Home
- DTIL vs AOMR Comparison
DTIL vs AOMR Comparison
Compare DTIL & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | AOMR |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.7M | 210.5M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DTIL | AOMR |
|---|---|---|
| Price | $7.50 | $9.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $45.00 | $11.08 |
| AVG Volume (30 Days) | ★ 299.3K | 89.6K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.18% |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $7.96 |
| 52 Week High | $9.62 | $10.14 |
Technical Indicators
Market Signals| Indicator | DTIL | AOMR |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 55.54 |
| Support Level | $6.62 | $8.72 |
| Resistance Level | $7.96 | $9.24 |
| Average True Range (ATR) | 0.41 | 0.22 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 72.64 | 78.06 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.